Teva Pharmaceutical Industries Ltd. $TEVA is Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management's 4th Largest Position

Key Points

• Mivtachim boosted its stake in Teva by 9.2% in Q4 to 1,875,521 shares, worth about $58.5 million, making TEVA its fourth-largest holding.
• Teva topped Q4 expectations with $0.96 EPS vs. $0.65 expected and $4.71B revenue vs. $4.36B, and issued FY2026 guidance of $2.57–$2.77 EPS (analyst consensus ~2.62).
• Insiders have been net sellers—selling 920,901 shares (~$30.06M) over the last three months—while institutional ownership is ~54%, with large stakes held by firms like Phoenix and Harel.

Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management boosted its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 9.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,875,521 shares of the company's stock after acquiring an additional 158,790 shares during the quarter. Teva Pharmaceutical Industries accounts for 8.1% of Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management's holdings, making the stock its 4th largest position. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management owned approximately 0.16% of Teva Pharmaceutical Industries worth $58,535,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Phoenix Financial Ltd. grew its holdings in Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the period. National Pension Service grew its holdings in Teva Pharmaceutical Industries by 24.2% in the third quarter. National Pension Service now owns 2,073,293 shares of the company's stock valued at $41,881,000 after purchasing an additional 404,526 shares during the period. Public Sector Pension Investment Board grew its holdings in Teva Pharmaceutical Industries by 11.5% in the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company's stock valued at $13,543,000 after purchasing an additional 69,000 shares during the period. Oak Harvest Investment Services acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth approximately $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company's stock worth $761,455,000 after acquiring an additional 4,306,363 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $35,692.09. Following the sale, the insider owned 10,914 shares in the company, valued at $345,646.38. The trade was a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28. Following the completion of the sale, the insider owned 224,940 shares in the company, valued at $6,779,691.60. This represents a 21.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 920,901 shares of company stock valued at $30,056,789. 0.54% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $30.66 on Friday. The stock's fifty day moving average is $31.22 and its two-hundred day moving average is $28.96. The firm has a market capitalization of $35.25 billion, a P/E ratio of 25.55, a price-to-earnings-growth ratio of 2.73 and a beta of 0.76. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.52 and a fifty-two week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on TEVA. Jefferies Financial Group lifted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a "buy" rating in a research note on Tuesday, January 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research note on Monday. Bank of America lifted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday, April 9th. Wall Street Zen raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 31st. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $38.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.